Interestingly, the expression level of neprilysin in the brain is distinctly down-regulated with increasing age and in the early stages of Alzheimer’s disease during which impaired metabolism of amyloid-β peptide 3 plays a central pathological role [31,32]. This evidence concerns the gene MME and early-onset autosomal dominant Alzheimer disease.